

Amendments to the Claims

1. (Cancelled)
2. (Cancelled)
3. (Cancelled)
4. (Currently Amended) A pharmaceutical composition for treating a gastrointestinal disorder in a patient, comprising duloxetine as the active ingredient [associated] with one or more pharmaceutically acceptable carriers.
5. (New) A method of treating gastrointestinal disorder in a patient comprising administering to the patient in need thereof duloxetine.
6. (New) The method of Claim 5 wherein the disorder is:
inflammatory bowel disease (IBD),
functional bowel disorders (FBD),
dyspepsia,
ileitis,
ischemic bowel disease,
irritable bowel syndrome,
gastroesophageal reflux or
diarrhea.
7. (New) The method of Claim 6 wherein the disorder is irritable bowel syndrome.